Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Jacoblo JACOBIO PHARMACEUTICALS GROUP CO . , LTD . 加科思 藥業 集團 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock code : 1167 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2026 AND APPOINTMENT OF VICE CHAIRPERSON OF THE BOARD AND CHANGES IN SENIOR MANAGEMENT The Board is pleased to announce the unaudited condensed consolidated interim results of our Group for the six months ended June 30 , 2026 , together with comparative figures for the six months ended June 30 , 2025 . BUSINESS HIGHLIGHTS During the Reporting Period , our Group continued advancing our drug pipeline and business operations , including the following milestones and achievements : Progress of Core Products R ( glecirasib , KRAS G12C inhibitor ) and sitneprotafib ( JAB - 3312 , SHP2 inhibitor ) NSCLC - > 2L NSCLC The market approval of glecirasib monotherapy in ≥2L NSCLC was granted by NMPA in patients with NSCLC harboring KRAS G12C mutations who have received at least one prior systemic therapy in May 2025. Glecirasib was successfully prescribed to the first patient within the same month and was then selected on the National Reimbursement Drug List in December 2025. The complete dataset of glecirasib in ≥2L NSCLC was published in Nature Medicine in January 2025 . 1